Lumanity Strategy & Insight’s Post

Excited to take a session on "Enhancing Evidence for Impact and Amplifying Market Access to Key Audiences" during my presentation at #MarCon2024, CIMICON Event Series, Berlin. I’ll be covering two critical topics: - Evidence Generation: What Has Changed? – Exploring how recent advancements have reshaped the landscape of evidence generation in healthcare. - Role of Real-World Evidence (RWE) in Evidence Generation – Highlighting the growing importance of RWE in delivering actionable insights and driving informed decision-making. Looking forward to insightful discussions! #MarketAccess #EvidenceGeneration #RWE #Pharma #HealthcareInnovation #EvidenceBasedMedicine

Don't miss our upcoming webinar, designed for client insight teams to hear from our experts, including Joel Shopland, Laura Galimam, Mary Stewart, and Damian Eade, as they share learnings from four of the presentations showcased during our recent internal research festival. The demand for agile and focused research insights comes against a backdrop of growing industry pressures. Staying ahead of the curve not only requires a deep understanding of the intricate interplay of market trends, competitive landscape, and patient needs, but the ability to adapt quickly to changing dynamics. Learn more and register at https://buff.ly/3XFaERf #researchinsights #markettrends #competitorlandscape #patientneeds #innovation #pharma

In this webcast, speakers from GSK, Medable, Inc, and Alcanza Clinical Research delve into the experiences of sites conducting digital and hybrid trials, and discuss the critical importance and benefits of implementing a change management strategy alongside a unified digital trial platform. Watch it here: https://lnkd.in/extmtmtw

Fierce Pharma had an excellent session with Murray Aitken and Anthony Mikulaschek from IQVIA discussing market trends in funding, spending, trial starts, and white space in #clinicaltrials. The white space between phases presents a great opportunity for us to decrease time to market. I've long believed that the future lies in rolling protocols. What strategies do you think can help shorten decision-making and administrative delays? #innovation #clinicalresearch #innovateinwhatyoudo

The latest episode of "Conversations with Anthony" is now live! Join me alongside A&M colleagues and life sciences experts Simon Joyeux and Ryan Donovan as we explore the evolving landscape of the industry. We discuss everything from deal volume & value to the regulatory environment, the resurgence of MedTech and pharma services demand and more! Tune in to gain insights from industry leaders and understand what's shaping the future of life sciences. Click here: https://okt.to/PJrQGE #AMon #lifesciences #privatequity

What's shaping the agenda for market access? This article from The Evidence Base® explores some of the current trends as well as issues and challenges faced by the access & pricing function. It was great to see our very own Nick Proctor sharing his views on price vs. value as part of the piece.   Read in full here: https://lnkd.in/emfQrQZh #healtheconomics #pharma #biopharma #healthpolicy #MarketAccess

What an exciting and energising PI Forum! How can we drive to reduce drug therapy costs and meet sustainability targets? Our industry certainly agrees that PI is in part the answer. Join the conversation! #sartorius #processintensification #innovation

In the first of a two-part feature, Joanne Walker of The Evidence Base® explores some of the current trends in #marketaccess, highlighting the issues and challenges faced by #stakeholders as they balance the need to ensure patients have timely access to new therapeutic innovations while navigating new technologies and evolving pressures to demonstrate the value of treatments to payers and providers. #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #inflationreductionact #jointclinicalassessment #healthequity

How can we ensure essential treatments reach those in need in a world of growing payer restrictions? https://ow.ly/nS5q50SV0mW The Dedham Group, in collaboration with MMIT (Managed Markets Insight & Technology), surveyed 300+ pharma and biotech leaders to explore current and future patient access challenges. Discover the insights shaping the future of patient access with The State of Patient Access – Inaugural Report by clicking the link in this post.

Interesting webinar coming up focused on global life science trends, including Europe.